Close Menu

NEW YORK (GenomeWeb) – San Diego-based diagnostics firm Genalyte today announced it has completed a $44M Series C financing round.

Khosla Ventures joined previous investors Redmile Group, Claremont Creek Ventures, and BioMed Ventures in the round.

Genalyte's CE-marked Maverick Detection System is intended for multiplexed, blood-based, point-of-care diagnostic testing. The firm said in a statement that it can provide results in 15 minutes. The platform is for research use only in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.